Spasm Provocation Testing
Spasm Provocation Testing - Related Videos
06:39
Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
0 Views •
Cited by 36 •
2016
Intracoronary acetylcholine testing has been established for the assessment of epicardial coronary spasm more than 30 years ago. Recently, the focus has shifted towards the microcirculation and it has been shown that microvascular spasm can be detected using ACH-testing. This article describes the ACH-test and its implementation in daily routine.
01:16
Vascular Spasm
0 Views •
2025
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...
11:17
Protocol for Repetitive Transcranial Magnetic Stimulation with Symptom Provocation to Treat Obsessive-compulsive Disorder
0 Views •
2025
This article presents a clinical protocol for repetitive transcranial magnetic stimulation (rTMS) with individualized symptom provocation in obsessive-compulsive disorder (OCD), following parameters from protocols cleared by the FDA.
06:18
Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm
0 Views •
Cited by 15 •
2021
Myocardial lactate production (coronary arterial-venous difference in serum lactate level) during coronary spasm provocation testing is considered as a highly sensitive marker that reflects acetylcholine-induced myocardial ischemia due to microvascular spasm. This article presents the procedures to assess myocardial lactate production for the diagnosis of coronary microvascular spasm.
07:47
Anxiety Testing
0 Views •
2023
Anxiety is a commonly observed behavioral disorder that stems from fear. It is described as increased restlessness, or unpleasant feelings of fear over anticipated events. Experimenters often use rodent models to better understand anxiety disorders in humans. They use different paradigms, like exposing rodents to bright spaces or loud sounds, which are known to induce fear. These tests combined with other interventions such as surgery or drug-administration may assist researchers in pinpointing...
FAQs
These vasoactive agents provide a controlled pharmacological challenge to vascular smooth muscle. Their administration can reveal whether an artery develops an abnormal contractile response, while the resulting symptoms, electrocardiographic changes, and temporary narrowing are assessed together. Comparing these observations helps clinicians characterize vascular reactivity rather than relying on chest-pain symptoms alone.
Temporary arterial narrowing provides angiographic evidence that vascular contraction occurred during the pharmacological challenge. When this finding corresponds with symptoms and electrocardiographic changes, it supports recognition of vasospastic angina as a cause of chest pain. The transient nature also allows investigators to examine abnormal reactivity without evaluating a continuously narrowed vessel.
The response can illuminate how endothelial function and vascular smooth-muscle signaling influence arterial tone. A test result therefore represents more than a clinical observation: it offers a way to examine how vasoactive stimulation produces contraction and how candidate drugs alter that response. This makes the approach relevant to pharmacological studies of pathological vasoconstriction.
During the controlled challenge, clinicians monitor several complementary outcomes: the patient's symptoms, electrocardiographic changes, and angiographic evidence of temporary arterial narrowing. Using these measures together links the subjective experience of chest pain with electrical cardiac effects and a visible vascular response. This combined assessment supports interpretation of abnormal coronary reactivity.
Clinicians may use the approach to help distinguish vasospastic angina from other causes of chest pain. In research and clinical pharmacology, investigators can use it to evaluate endothelial function, characterize responses to vasoactive drugs, and study therapies designed to prevent or relieve pathological vasoconstriction. Its value therefore spans diagnosis, mechanism-focused research, and treatment evaluation.
The test can show whether a vasoactive challenge produces symptoms, electrocardiographic changes, and temporary arterial narrowing, while also characterizing the associated vascular response. In pharmacology studies, these outcomes help assess drug effects and support evaluation of therapies intended to prevent or relieve abnormal vasoconstriction. The findings connect vascular physiology with clinically relevant cardiac manifestations.